Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221010 | 0.78 | NPY1R (0.38) | HRH4 | |
| SCHEMBL605084 | 0.77 | HRH4 (0.38) | HRH4TLR8HRH3CYP2D6CYP2C19 | |
| SCHEMBL605028 | 0.76 | HRH4 (0.48) | HRH4TLR8SMN1; SMN2KDM4E | |
| SCHEMBL605029 | 0.76 | HRH4 (0.48) | HRH4TLR8SMN1; SMN2KDM4E | |
| SCHEMBL605196 | 0.75 | HRH4 (0.37) | HRH4TLR8HRH3CYP2D6CYP2C19 | |
| SCHEMBL19104420 | 0.73 | HRH4 (0.85) | HRH4TLR8KDM4E | |
| SCHEMBL7366748 | 0.69 | CYP2D6 (0.47) | HRH4TLR8SMN1; SMN2HRH3CYP2D6 | |
| SCHEMBL604879 | 0.68 | HRH3 (0.42) | HRH4TLR8HRH3CYP2D6CYP2C19 | |
| SCHEMBL605083 | 0.67 | HRH4 (0.48) | HRH4TLR8HRH3 | |
| SCHEMBL3199075 | 0.67 | PLAU (0.40) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2858647-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013182711-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2013-12-12 | — | — | WO | disclosed |
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-20110160452-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-20110160452-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885TLR8 393/4885SMN1; SMN2 4360/4885 |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | HRH4 1/4885TLR8 304/4885SMN1; SMN2 4702/4885 |
| US-20110160452-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885TLR8 393/4885SMN1; SMN2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.